Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 131

recruiting
3 982
countries
28
conditions
2 106

2 729 trials match your criteria

Obesity+1

Not recruiting

Study on the Effects of RO7204239 and Tirzepatide for Weight Loss in Patients with Obesity or Overweight with a Weight-Related Health Issue

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tirzepatide

Colitis ulcerative

Not recruiting

Study on the Effectiveness and Safety of SAR441566 for Adults with Moderate-to-Severe Ulcerative Colitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years

Endocrine ophthalmopathy

Not recruiting

Study on the Safety and Tolerability of VRDN-003 for Patients with Thyroid Eye Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:VRDN-003

Obesity+1

Not recruiting

Study on Maridebart Cafraglutide for Adults with Type 2 Diabetes and Obesity or Overweight

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide

Macular oedema+2

Not recruiting

Study on the Use of SB11 Pre-Filled Syringe for Patients with Wet Age-Related Macular Degeneration, Macular Edema from Retinal Vein Occlusion, or Myopic Choroidal Neovascularization

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab

Pulmonary arterial hypertension

Not recruiting

Study on the Safety and Tolerability of Sotatercept for Patients with Pulmonary Arterial Hypertension

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept

Obesity+1

Not recruiting

Study on the Effectiveness and Safety of Maridebart Cafraglutide for Adults with Obesity or Overweight Without Type 2 Diabetes

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide

Endocrine ophthalmopathy

Not recruiting

Study on the Effectiveness and Safety of VRDN-003 for Patients with Chronic Thyroid Eye Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:VRDN-003

Neovascular age-related macular degeneration

Not recruiting

Study Comparing EYP-1901 and Aflibercept for Patients with Wet Age-Related Macular Degeneration

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept

Hidradenitis

Not recruiting

Study on the Effects of Remibrutinib for Adults with Moderate to Severe Hidradenitis Suppurativa

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Remibrutinib

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of Tildrakizumab for Patients with Moderate to Severe Genital Psoriasis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tildrakizumab

Myasthenia gravis

Not recruiting

Study on the Effects of Remibrutinib for Patients with Generalized Myasthenia Gravis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.